JNCI Journal of the National Cancer Institute最新文献

英文中文

Cervical cancer incidence rates by birth cohort against the backdrop of human papillomavirus vaccination in the United States. 美国人乳头瘤病毒疫苗接种背景下的出生队列宫颈癌发病率

IF 7.2 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute

Pub Date : 2026-01-07 DOI: 10.1093/jnci/djaf374

Chenxi Jiang, Philip S Rosenberg, Ahmedin Jemal, Hyuna Sung

Previous cervical cancer incidence trend analyses primarily used period-based approaches, limiting assessment of generational risk shifts against the backdrop of human papillomavirus (HPV) vaccination. Using U.S. Cancer Statistics data and age-period-cohort modeling, we estimated fitted incidence rates at ages 30-31 across birth cohorts (1917-1919 to 1999-2001), adjusted for period deviation. Incidence rates decreased by 1.9% per birth year (95%CI, -1.8% to -2.1%) up to 1951-1953 cohorts, then decelerated to 0.3% annually (95%CI, -0.4% to -0.2%). Starting with 1987-1989 cohort, incidence rates dropped sharply by 10.5% annually (95%CI, -12.7% to -8.4%). Compared with 1970-1979 cohorts, 1990-1999 cohorts had a 54% lower incidence rate (10.2 vs 4.7 per 100,000; rate ratio = 0.46; 95%CI, 0.42 to 0.50). The markedly lower risk among post-1987-1989 cohorts suggests a future reduction in population-level burden as these cohorts age. The finding also has implications for reinforcing HPV vaccination efforts and informing discussions on raising the screening initiation age.

以前的宫颈癌发病率趋势分析主要使用基于时期的方法，限制了在人乳头瘤病毒（HPV）疫苗接种背景下对代际风险转移的评估。使用美国癌症统计数据和年龄-时期-队列模型，我们估计了出生队列（1917-1919至1999-2001）中30-31岁年龄段的拟合发病率，并根据时期偏差进行了调整。在1951-1953年的队列中，发病率每出生年下降1.9% (95%CI, -1.8%至-2.1%)，然后每年减速至0.3% （95%CI, -0.4%至-0.2%）。从1987-1989年队列开始，发病率每年急剧下降10.5% （95%CI, -12.7%至-8.4%）。与1970-1979年队列相比，1990-1999年队列的发病率降低了54% （10.2 vs 4.7 / 100000；发病率比= 0.46;95%CI, 0.42 ~ 0.50）。1987-1989年后人群的风险显著降低表明，随着这些人群年龄的增长，未来人口水平的负担将减少。这一发现也对加强HPV疫苗接种工作和提高筛查起始年龄的讨论具有启示意义。

{"title":"Cervical cancer incidence rates by birth cohort against the backdrop of human papillomavirus vaccination in the United States.","authors":"Chenxi Jiang, Philip S Rosenberg, Ahmedin Jemal, Hyuna Sung","doi":"10.1093/jnci/djaf374","DOIUrl":"https://doi.org/10.1093/jnci/djaf374","url":null,"abstract":"Previous cervical cancer incidence trend analyses primarily used period-based approaches, limiting assessment of generational risk shifts against the backdrop of human papillomavirus (HPV) vaccination. Using U.S. Cancer Statistics data and age-period-cohort modeling, we estimated fitted incidence rates at ages 30-31 across birth cohorts (1917-1919 to 1999-2001), adjusted for period deviation. Incidence rates decreased by 1.9% per birth year (95%CI, -1.8% to -2.1%) up to 1951-1953 cohorts, then decelerated to 0.3% annually (95%CI, -0.4% to -0.2%). Starting with 1987-1989 cohort, incidence rates dropped sharply by 10.5% annually (95%CI, -12.7% to -8.4%). Compared with 1970-1979 cohorts, 1990-1999 cohorts had a 54% lower incidence rate (10.2 vs 4.7 per 100,000; rate ratio = 0.46; 95%CI, 0.42 to 0.50). The markedly lower risk among post-1987-1989 cohorts suggests a future reduction in population-level burden as these cohorts age. The finding also has implications for reinforcing HPV vaccination efforts and informing discussions on raising the screening initiation age.","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RE: Impact of daily adaptive head and neck radiotherapy on toxicity and quality of life: results of the DARTBOARD phase II randomized trial. 每日适应性头颈部放疗对毒性和生活质量的影响：DARTBOARD II期随机试验的结果。

IF 7.2 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute

Pub Date : 2026-01-01 DOI: 10.1093/jnci/djaf300

Francesco Fiorica

引用次数: 0

Response to Fiorica. 对费奥里卡的回应。

IF 7.2 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute

Pub Date : 2026-01-01 DOI: 10.1093/jnci/djaf306

David J Sher, Dominic H Moon

引用次数: 0

Cardiovascular risk in the aging cancer survivor population. 老年癌症幸存者的心血管风险

IF 7.2 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute

Pub Date : 2026-01-01 DOI: 10.1093/jnci/djaf299

Susan F Dent, Heather Moore, Avirup Guha

引用次数: 0

Response to Orlandi. 对奥兰多的回应。

IF 7.2 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute

Pub Date : 2026-01-01 DOI: 10.1093/jnci/djaf320

Paolo Tarantino, Do Lee, Pamela R Soulos, Sarah Sammons, Maryam Lustberg

引用次数: 0

Real-world vs unreal eligibility. 真实世界vs虚幻世界。

IF 7.2 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute

Pub Date : 2026-01-01 DOI: 10.1093/jnci/djaf292

Howard S Hochster

引用次数: 0

RE: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. RE：转移性乳腺癌患者接受曲妥珠单抗后的后续治疗方案的结果。

IF 7.2 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute

Pub Date : 2026-01-01 DOI: 10.1093/jnci/djaf319

Armando Orlandi

引用次数: 0

Accelerometer-derived concentrated physical activity pattern and mortality in cancer survivors: the UK Biobank accelerometry study. 加速度计衍生的集中体力活动模式和癌症幸存者的死亡率：英国生物银行加速度计研究。

IF 7.2 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute

Pub Date : 2026-01-01 DOI: 10.1093/jnci/djaf146

Haoting Shi, Zheshen Han, Qing Qu, Jingxuan Huang, Ruixin Pan, Jing Yu, Chao Hu, Qiaoge Chi, Shi Zhao, Jinliang Wang, Xiaosong Chen, Kunwei Shen, Rong Cai

Although reduced mortality associated with moderate-to-vigorous physical activity has been reported among cancer survivors, the benefits of a concentrated physical activity pattern remain unclear. This prospective cohort study included 6075 cancer survivors from the UK Biobank accelerometry dataset: 2390 (39.3%) were inactive (<150 minutes/week), 1295 (21.3%) were active concentrated (≥150 minutes/week and achieved ≥50% total moderate-to-vigorous physical activity within 1-2 days), and 2390 (39.3%) were active regular (≥150 minutes/week but other than concentrated). After a median follow-up of 8 years (interquartile range [IQR] = 7.5 to 8.5 years), 634 deaths occurred. Active concentrated and regular patterns were associated with similar reduced all-cause mortality (hazard ratio [HR] = 0.72, 95% CI = 0.60 to 0.86; HR = 0.71, 95% CI = 0.56 to 0.89) and noncancer mortality (HR = 0.66, 95% CI = 0.47 to 0.92; HR = 0.56, 95% CI = 0.35 to 0.89). These findings highlight the concentrated physical activity pattern as a lifestyle intervention for cancer survivors.

虽然在癌症幸存者中有报道称中至高强度体育活动（MVPA）可降低死亡率，但集中体育活动模式的益处尚不清楚。这项前瞻性队列研究包括来自UK Biobank加速度计数据集的6075名癌症幸存者：2390名（39.3%）为不活动（< 150分钟/周），1295名（21.3%）为集中活动（≥150分钟/周，并在1-2天内达到≥50%的总MVPA）， 2390名（39.3%）为常规活动（≥150分钟/周，但非集中）。中位随访8年后（四分位数范围7.5-8.5），发生634例死亡。活跃的集中模式和常规模式均与全因死亡率降低相关(HR 0.72 [95% CI, 0.60-0.86]；HR 0.71 [95% CI, 0.56-0.89])和非癌症死亡率(HR 0.66 [95% CI, 0.47-0.92]；Hr 0.56 [95% ci, 0.35-0.89])。这些发现强调了集中的PA模式作为癌症幸存者的生活方式干预。

{"title":"Accelerometer-derived concentrated physical activity pattern and mortality in cancer survivors: the UK Biobank accelerometry study.","authors":"Haoting Shi, Zheshen Han, Qing Qu, Jingxuan Huang, Ruixin Pan, Jing Yu, Chao Hu, Qiaoge Chi, Shi Zhao, Jinliang Wang, Xiaosong Chen, Kunwei Shen, Rong Cai","doi":"10.1093/jnci/djaf146","DOIUrl":"10.1093/jnci/djaf146","url":null,"abstract":"Although reduced mortality associated with moderate-to-vigorous physical activity has been reported among cancer survivors, the benefits of a concentrated physical activity pattern remain unclear. This prospective cohort study included 6075 cancer survivors from the UK Biobank accelerometry dataset: 2390 (39.3%) were inactive (<150 minutes/week), 1295 (21.3%) were active concentrated (≥150 minutes/week and achieved ≥50% total moderate-to-vigorous physical activity within 1-2 days), and 2390 (39.3%) were active regular (≥150 minutes/week but other than concentrated). After a median follow-up of 8 years (interquartile range [IQR] = 7.5 to 8.5 years), 634 deaths occurred. Active concentrated and regular patterns were associated with similar reduced all-cause mortality (hazard ratio [HR] = 0.72, 95% CI = 0.60 to 0.86; HR = 0.71, 95% CI = 0.56 to 0.89) and noncancer mortality (HR = 0.66, 95% CI = 0.47 to 0.92; HR = 0.56, 95% CI = 0.35 to 0.89). These findings highlight the concentrated physical activity pattern as a lifestyle intervention for cancer survivors.","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"170-174"},"PeriodicalIF":7.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stat Bite: Productivity losses from premature cancer mortality in 2022. 统计数据：2022年癌症过早死亡造成的生产力损失。

IF 7.2 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute

Pub Date : 2026-01-01 DOI: 10.1093/jnci/djaf330

Yek-Ching Kong, Freddie Bray, Isabelle Soerjomataram

引用次数: 0

Liquid biopsy for very early detection of HPV-associated oropharyngeal cancer. 液体活检用于hpv相关口咽癌的早期检测。

IF 7.2 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute

Pub Date : 2026-01-01 DOI: 10.1093/jnci/djaf302

David M Routman, Axel M Hidalgo, Aadel A Chaudhuri

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

JNCI Journal of the National Cancer Institute

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀